What's the difference between single, dual, and triple agonists?

Semaglutide hits GLP-1 only, tirzepatide adds GIP (dual), and retatrutide adds glucagon (triple), which boosts metabolic rate. Each added receptor tends to increase potency.

Is retatrutide FDA-approved?

Not yet. As of mid-2026 it is still investigational despite strong TRIUMPH-1 Phase 3 results. Gray-market versions carry real contamination and dosing risks.

Answer

Retatrutide vs tirzepatide vs semaglutide: what's the difference?

Q: Is retatrutide better than tirzepatide?

On raw weight loss, its Phase 3 data (about 25-30%) beats tirzepatide. But retatrutide is still investigational and not FDA-approved, with less long-term safety data. Tirzepatide is available now.

GLP-1 Agonists glp-1 retatrutide tirzepatide semaglutide

Verdict

Not enough evidence

Retatrutide causes more weight loss than tirzepatide, and tirzepatide more than semaglutide.

No counted mention yet.

By Arun AgrahriLast reviewed 26 Aug 2026

Based on what researchers say in public interviews on YouTube. Educational only, not medical advice. Ask a qualified clinician before changing a supplement, medication, treatment, or testing plan.

Short answer

Each adds a receptor. Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist (about 15% weight loss). Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist and more potent. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) that hit about 25-30% in its 2026 Phase 3 trial, but it is still investigational, not FDA-approved. More potency means faster loss and more need to defend muscle.

Leaning for

GLP-1 drugs are worth taking for people with obesity.

The verdict on GLP-1 Agonists overall. 18 sources: 6 positive, 9 partly, 3 negative

What the evidence says

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

Not enough evidence
Retatrutide causes more weight loss than tirzepatide, and tirzepatide more than semaglutide.

No counted mention yet.

Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent

Detailed Answer

Retatrutide causes more weight loss than tirzepatide, and tirzepatide more than semaglutide. Think of the three as successive generations, each adding a receptor.

Semaglutide

Semaglutide sells as Ozempic for diabetes and Wegovy for obesity. It is a single GLP-1 receptor agonist and the most established of the three, with the deepest cardiovascular outcome data. Trials put its average weight loss at roughly 15% of bodyweight.

Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is a dual agonist that hits GIP and GLP-1 receptors. Zachary Knight, a neuroscientist and guest on Andrew Huberman's show, calls it a better drug than Ozempic in almost every respect, and people lose more weight on it.

Retatrutide

Retatrutide is the next step, a triple agonist that adds a glucagon receptor to GLP-1 and GIP. Glucagon raises metabolic rate by making mitochondria burn energy less efficiently, on top of the appetite suppression. Its pivotal Phase 3 trial, TRIUMPH-1, reported at the American Diabetes Association meeting in June 2026.

Average weight loss ran roughly 25% of bodyweight at the top dose over 80 weeks and climbed toward 30% by week 104. More than a quarter of participants lost 35% or more, close to the results of weight-loss surgery.

Two caveats

Retatrutide is still investigational and not FDA-approved, and the tapes on the record touch on the triple-agonist idea only in passing. It also carries its own early signals, including a rise in resting heart rate. Across all three, more potency means faster and deeper weight loss, and more work to protect muscle with protein and resistance training.